Jim Cramer takes a look at the big four stocks from Warren Buffett's portfolio. Are they right for your portfolio?» Read More
Drug giant Merck said it will buy Cubist and its slate of medicines administered in hospitals, many for bacterial infections, for about $9.5 billion.
The Fast Money traders share their final trades of the day and what they'll be trading tomorrow.
The "Black Card" is just one of many elite credit cards offering special incentives to cardholders.
Jim Cramer sits down with Enbridge CEO Albert Monaco to discuss the way to play crude in a low priced environment.
Jim Cramer has a personal connection to why he approves of Merck's acquisition of Cubist. Find out why.
Goldman Sachs already appears to be having second thoughts on its tepid forecast for 2015.
Check out which companies are making headlines after the bell Monday: H&R Block, Verizon, United Airlines and more.
Buying a call is one of the simplest options strategies. So how, exactly, does it work?
Consumers are choosing Apple's high-end iPhones with more memory as they shoot and consume more video, according to Citigroup.
Three small-cap drug firms are consistently the best biotech performers following the start of the American Society of Hematology's annual meeting.
Small investors loaded up on shares of energy stocks last month amid an epic decline of 40 percent in the price of oil from a recent high in July.
Carter Worth of Sterne Agee says Starbucks shares are about to get hyper.
NYSE floor trader Kenny Polcari offers up his 2015 outlook and what what sectors he thinks are going to be hot.
Technology investors are gearing up for a holiday shopping spree. LendingClub headlines a banner week for Internet IPOs.
Vastly divergent policies from global central banks have sparked investor concern that 2015 is set to be a turbulent year.
Traders will be searching for any signs the economy and job market are really kicking into a higher gear, as Friday's jobs report suggests.
Wrap it up and put on a bow, "Mad Money" host Jim Cramer thinks these stocks belong under the tree.
U.S. outperformance has been the key to stocks, currencies, and commodities in 2014. But can the trend continue?
Jim Cramer reflects on AbbVie's decision to drop the biggest merger of the year—and yet, this stock is still on fire.
The "Fast Money" traders give their final trades of the day.
Get the best of CNBC in your inbox